A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
PL BioScience introduced the world’s first artificial human platelet lysate (HPL), a xeno-free, lab-made cell culture supplement developed with DewCell Biotherapeutics’ artificial platelet technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback